Bextra (valdecoxib), a new COX-2 inhibitor
January 2002
You'll hear about Bextra (valdecoxib), a new COX-2 inhibitor.
It's being co-marketed now in the U.S. by Pharmacia and Pfizer...the same companies that market Celebrex (celecoxib).
Expect it to be approved in Canada sometime this year.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive